In February 2019, the Company implemented corporate changes to focus its resources on advancing its clinical-stage therapeutic candidates. As a result, the Company is concentrating on completing the SER-287 Phase 2b study in mild-to-moderate UC, obtaining results from the ongoing SER-109 Phase 3 study for recurrent CDI, advancing the SER-401 Phase 1b study, to evaluate augmenting checkpoint inhibitor response in patients with metastatic melanoma and advancing SER-301 into clinical development. In connection with the prioritization of these therapeutic candidates, the Company made changes to its management team and reduced headcount by approximately 30 percent.

During the year ended December 31, 2019 the Company recorded charges of $1,492, related to severance and other termination benefits. No restructuring charges were recorded during the years ended December 31, 2018 and 2017. During the year ended December 31, 2019 the Company paid $1,299 related to the restructuring and it expects to pay approximately $193 in 2020.

The outstanding restructuring liabilities are included in accrued expenses and other current liabilities on the consolidated balance sheets. As of December 31, 2019, the components of the outstanding restructuring liabilities included in accrued expenses and other current liabilities were as follows:

	Employee Severance and Other Benefits
Restructuring expenses	$	1,492
Cash payments	$	(1,299	)
Liability included in accrued expenses and other current liabilities at December 31, 2019	$	193